- Home
- LI vs ROIV Comparison
LI vs ROIV Comparison
Compare LI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LI | ROIV |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | China | United Kingdom |
| Employees | 30728 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3B | 20.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LI | ROIV |
|---|---|---|
| Price | $17.66 | $27.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | $19.66 | ★ $28.94 |
| AVG Volume (30 Days) | 2.6M | ★ 4.5M |
| Earning Date | 05-28-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,053,000.00 |
| Revenue This Year | $18.98 | N/A |
| Revenue Next Year | $22.72 | $744.61 |
| P/E Ratio | $29.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.71 | $10.58 |
| 52 Week High | $32.03 | $30.33 |
Technical Indicators
Market Signals| Indicator | LI | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 43.28 | 46.06 |
| Support Level | $17.45 | $26.94 |
| Resistance Level | $18.94 | $27.94 |
| Average True Range (ATR) | 0.33 | 0.90 |
| MACD | -0.11 | -0.18 |
| Stochastic Oscillator | 20.29 | 24.04 |
Price Performance
Historical ComparisonAbout LI Li Auto Inc.
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 400,000 NEVs in 2025, accounting for about 3% of China's passenger new energy vehicle market. Beyond Li One, the company expands its product line, including both BEVs and PHEVs, to target a broader consumer base.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.